InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called  C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.

These often arise from high systemic exposure after intravenous administration of the drug as only 0.1% – 2% enter the brain. Locally applied C-Locked biologics stay in the brain and, even if they should leak, are rapidly degraded, thus offering a much-improved therapeutic window.